相关实验视频

Updated: May 25, 2025

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

探索布莱维尔提德治疗响应的预测因素在肝炎德尔塔阳性患者

Verdiana Zulian¹, Leonidas Salichos², Chiara Taibi³

¹Virology Laboratory, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, 00149 Rome, Italy.

|February 26, 2025

概括

较低的抗HBcIgG基线水平和特定的D型肝炎病毒RNA结构预测了共感染患者的布莱维治疗成功. 这一发现有助于理解B型/D型肝炎病毒共感染的治疗反应.

科学领域:

肝病学肝病学是一种肝病学.
病毒学病毒学
分子生物学分子生物学

背景情况:

肝炎三角病毒 (HDV) 感染是病毒性肝炎的最严重形式.
布列维尔提德 (BLV) 为HBV/HDV共感染提供了一种新的治疗方法,但应答率各不相同.
预测治疗成功对于优化患者的治疗结果至关重要.

研究的目的:

为了确定预测Bulevirtide (BLV) 在HBV/HDV共感染患者治疗成功的临床,病毒学和多态因素.
分析基线特征和病毒因素对治疗反应的影响.
探索HDV RNA结构与治疗疗效之间的潜在相关性.

主要方法:

30名HBV/HDV共感染的患者接受了BLV单疗法 (2毫克/天) 24-48周.
基线和随访血清样本被分析为HDV RNA,HBV DNA,HBsAg,HBcrAg和抗HBc IgG.
进行了全基因组HDV测序,遗传学分析,HDAg蛋白序列分析和HDV RNA二次结构分析.

主要成果:

到第48周,58%的患者实现了病毒学反应 (HDV RNA无法检测或≥2日志下降).
较低的抗HBcIgG基线水平与病毒学反应显著相关 (p=0.0001).
高密度病毒基因型1e占主导地位;没有HDAg多态度预测反应,但高密度病毒RNA二次结构 (编辑部位附近的内部循环) 可能会影响疗效.

结论:

较低的抗HBcIgG基线水平是HBV/HDV共感染中对BLV的阳性病毒学反应的强有力的预测指标.
肝脏的炎症状态,由抗HBcIgG水平表明,似乎影响治疗的成功.
高密度病毒RNA二次结构,特别是编辑效率,可能在BLV治疗反应中发挥作用,需要进一步调查.

关键词:

抗HBc IgG 的抗HBc IgG 的抗HBc IgG.在这里,我们可以看到HDV HDV.抗病毒治疗是一种抗病毒治疗.布莱维尔提德 (Bulevirtide) 是一种蛋白质的化合物.遗传变异性遗传变异性

更多相关视频

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

相关概念视频

Cross-reactivity

Cross-reactivity

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...